Halozyme Therapeutics valuation

HALO · NASDAQ · USD

Compare Halozyme Therapeutics
$95.97Change from previous close: −0.55%Absolute change: −$0.53

Close · November 17, 2026

Valuation

The P/E ratio is 38.3. The average price target of 9 analysts is $108.78.

Data as of November 17, 2026

Halozyme Therapeutics compared with similar companies

Halozyme Therapeutics's P/E (trailing 12 months): 38.3, in line with the median of a group of 7 similar companies (38.3).

Halozyme Therapeutics's metrics compared with similar companies
MetricHalozyme TherapeuticsMedian25th–75th percentileBand
P/E (trailing 12 months)38.338.319.1 – 69.1Middle
Forward P/E9.1915.59.15 – 25.0Middle
EV/EBITDA11.617.013.4 – 27.9Low
Price/book87.57.544.09 – 14.6High
Price/sales7.527.234.95 – 9.17Middle
Gross margin76.3%77.3%71.2% – 91.5%Middle
Operating margin56.8%19.5%-5.3% – 29.2%High
Net margin24.9%4.4%-5.7% – 30.2%Middle
ROE173.7%8.3%-4.2% – 88.3%High
Debt/equity15.20.300.06 – 0.75High

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Halozyme Therapeutics: valuation over time

On the latest fiscal year's earnings (2025), Halozyme Therapeutics's P/E today is 37.4, above the median of its last 7 fiscal years (26.3; between 13.9 and 46.9 from 2017 to 2025). Relative to earnings, the stock costs more than it used to.

Halozyme Therapeutics P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/E
2025$67.30$2.5626.3
2024$47.81$3.4313.9
2023$36.96$2.1017.6
2022$56.90$1.4439.5
2021$40.21$2.7414.7
2020$42.71$0.9146.9
2019$17.73-$0.50—
2018$14.63-$0.56—
2017$20.26$0.4545.0
2016$9.88-$0.81—

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
$14.67B
Enterprise value
$13.21B
EV/revenue
7.33

Profitability and growth

ROA
25.5%
ROIC
28.2%
Revenue growth (year over year)
47.7%
Earnings growth (year over year)
42.9%

Financial health

Total cash
$1.07B
Total debt
$3.28B
Current ratio
2.71
Quick ratio
1.99
Altman Z-Score
3.45
Piotroski F-Score
6.00

Analysts and estimates

Average price target
$108.78
High price target
$130.00
Low price target
$78.00
Analysts with a price target
9
Consensus
Buy

Shares and trading

Beta
0.88
Average volume
2.29M
Shares outstanding
114.01M
Float
112.7M
Institutional ownership
100.0%
Insider ownership
1.1%
Short interest (% of float)
12.1%
Short ratio (days)
6.19